[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guizhou Provincial People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100627288","early-phase-1-study-on-the-safety-and-tolerability-of-postoperative-radiotherapy-concurrent-with-cdk46-inhibitors-in-hrher2--high-risk-breast-cancer-100627288",false,"NCT07446686","Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4\u002F6 Inhibitors in HR+\u002FHER2- High-Risk Breast Cancer","Inclusion Criteria:\n\n* Age is 18-75 years old, gender is female\n* Postoperative pathological examination confirmed HR+, HER2- invasive breast cancer:\n\n  1. ER positivity and\u002For PR positivity is defined as: all positively stained tumor cells The proportion of tumor cells is ≥10%;\n  2. HER2 negativity is defined as: 0\u002F1+ by standard immunohistochemistry (IHC) test; ISH test was negative.\n* The time from radical surgery or breast-conserving surgery to randomization shall not exceed 6 months;\n* Postoperative pathological examination after radical surgery revealed the presence of lymph nodes in the axilla on the ipsilateral side of the breast lesion.\n\nMetastasis (lymph node micrometastases, ipsilateral internal mammary lymph nodes and supraclavicular lymph nodes are allowed) metastasis, but the number of metastases to the ipsilateral internal mammary lymph nodes and supraclavicular lymph nodes is not included in the positive calculation of sexual lymph nodes), the specific requirements are as follows:\n\n1\\) The number of lymph node metastases is ≥ 4; 2) When the number of lymph node metastases is 1 to 3, at least one of the following high-risk factors must be met: i. Postoperative pathological examination shows that the diameter of the primary tumor is ≥5cm; ii. The histological grade of the primary tumor is grade III (excluding grade II-III); iii. There is residual invasive cancer in breast lesions after neoadjuvant treatment; iv. Ki-67≥30%.\n\n* Eastern Cooperative Oncology Group (ECOG) physical status score is 0 -2 points.\n* With my consent and having signed the informed consent form, I am willing and able to comply with the planned interview.\n\ninspections, study treatment plans, laboratory tests, and other research procedures.\n\nExclusion Criteria:\n\n* Pathological examination diagnosed as HER2-positive breast cancer (HER2-positive definition: standard immune Histochemistry (IHC) test is 3+ or ISH test is positive).\n* Local or regional recurrence of breast malignant tumors.\n* The clinical stage of the tumor is stage IV (metastatic) breast cancer.\n* Bilateral breast cancer (including contralateral carcinoma in situ).\n* History of serious lung diseases such as interstitial pneumonia.\n* Have received CDK4\u002F6 inhibitor treatment or other anti-tumor biological treatments in the past therapy, targeted therapy or tumor immunotherapy.\n* Have undergone major surgical operations, any investigational drugs, or others within 4 weeks before randomization Anticancer treatment or use of immunomodulators (excluding surgery, chemotherapy, radiotherapy and endocrine therapy).\n* The presence of other serious physical or mental illnesses or laboratory abnormalities that may increase participation The risks of the research, or interference with the research results, and the researcher's opinion that he is not suitable to participate in this research study patients.","FEMALE","18 Years","75 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The investigators combined postoperative radiotherapy with CDK4\u002F6 inhibitors ± endocrine adjuvant therapy to explore the tolerability and safety of this treatment regimen in HR+\u002FHER2- postoperative high-risk breast cancer patients. During the study, investigators also utilized PRO scales (FACT-B, FACT-ES, FACT-F) to evaluate patients' multidimensional experiences, such as physical function, emotional state, and treatment-related symptoms, thereby obtaining more authentic and reliable data for symptom assessment and patient benefit.",[26],"Breast Cancer","NOT_YET_RECRUITING","2026-02-25",{"date":30,"type":31},"2026-03-03","ACTUAL",{"date":33,"type":20},"2026-04-01",{"date":35,"type":20},"2027-06-30",{"name":37,"class":38},"Guizhou Provincial People's Hospital","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":45,"targetDuration":4,"studyType":46,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},"100512256","study-on-the-relationship-between-plasma-mrd-and-cfdna-hpv-and-the-efficacy-and-prognosis-of-locally-advanced-cervical-cancer-after-concurrent-chemoradiotherapy-100512256","NCT05950087","Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy","Inclusion criteria\n\n* Age: ≥ 18 years old, ≤ 75 years old.\n* Pathological histologic confirmation of cervical cancer.\n* Imaging or PET\u002FCT examination can be performed to understand the tumor and complete all follow-up.\n* Measurable lesions before treatment.\n* Good physical condition: ECOG score 0-1 (or KPS score 70-100).\n* Estimated survival≥ 6 months.\n* The baseline blood routine and biochemical indexes before radiotherapy and chemotherapy met the following standards: hemoglobin ≥ 80g\u002FL, absolute neutrophil count (ANC) ≥ 1.5×109\u002FL, platelet ≥ 100×109\u002FL, ALT, AST ≤ 2.5 times the normal upper limit; Serum albumin ≥ 30 g\u002FL.\n* There are three preoperative items: if the patient has syphilis, plum repellent therapy is required before treatment.\n* The patient has no history of allergy to rubber products.\n* Cardiopulmonary function is basically normal\n\nExclusion Criteria:\n\n* Those who are allergic to rubber products.\n* Those with severe acute infection and uncontrolled or purulent and chronic infection wounds that do not heal, chronic hepatitis B active stage, active tuberculosis, syphilis outbreak and AIDS.\n* Patients with pre-existing severe heart disease, including: congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and intractable hypertension.\n* Those with neurological or psychiatric diseases or mental disorders that are not easy to control, poor compliance, unable to cooperate with and describe treatment responses, uncontrolled primary brain tumors or central nervous system metastases, and those with obvious cranial hypertension signs or neuropsychiatric symptoms.\n* with malignant serous effusion.\n* History of severe enteritis and cystitis, bleeding, intestinal perforation, rectovaginal fistula, rectoval bladder fistula, etc.\n* Those who have participated in other clinical trials.\n* Other situations in which the investigator believes that the subject is not suitable to participate in this experiment",{"count":19,"type":20},"OBSERVATIONAL","Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.",[49],"Locally Advanced Cervical Cancer","RECRUITING","2023-07-14",{"date":53,"type":31},"2023-07-18",{"date":55,"type":31},"2022-11-01",{"date":57,"type":20},"2026-12-31",{"name":37,"class":38},1,""]